Sobi Announces Positive Phase 3 REDUCE-2 Data for Pozdeutinurad

Sobi reported positive late-breaking Phase 3 REDUCE-2 results for investigational gout drug pozdeutinurad (AR882), presented at ACR Convergence 2026. The once-daily oral URAT1 inhibitor produced clinically meaningful, durable reductions in serum urate over 12 months, and significantly more patients reached target levels than with placebo. Its safety profile was generally comparable to placebo; the article did not report financial figures or a stock-price reaction.